Type
1.
Hunt WTNH, Hùng NT, Tru’ò’ng NN, Nikolaou V, Khoa NDD, Ly TH. A case-control study comparing the Dermatology Life Quality Index (DLQI) ratings of patients undergoing leprosy treatment, people cured of leprosy, and controls in Vietnam. Leprosy review [Internet]. 2018;89(1):46-55. Available from: https://leprosyreview.org/article/89/1/04-6055
Type
1.
Gyapong J, Owusu I, Vroom F, Mensah E, Gyapong M. Elimination of lymphatic filariasis: current perspectives on mass drug administration. Research and Reports in Tropical Medicine. 2018;Volume 9:18-33.
Type
1.
Krentel A, Wellings K. The role of gender relations in uptake of mass drug administration for lymphatic filariasis in Alor District, Indonesia. Parasites & vectors [Internet]. 2018;11(1):179. Available from: https://parasitesandvectors.biomedcentral.com/articles/10.1186/s13071-018-2689-8
Type
1.
Kim. The Trend of Leprosy Treatment. Korean Leprosy Bulletin. 2015;48(1):13-5.
Type
1.
Park, Kim, Ahn. Clinical characteristics and Treatment of Paraffinomas in patients with Hansen disease. Korean Leprosy Bulletin. 2013;46(1):41-8.
Type
1.
Vollset M. Globalizing leprosy: A transnational history of production and circulation of medical knowledge, 1850s-1930s [Internet]. [Bergen]: University of Bergen; 2013. Available from: http://bora.uib.no/handle/1956/16782?locale-attribute=en
Type
1.
Gurjon-Oil Treatment of Leprosy. Edinburgh medical journal [Internet]. 1877;22(9):845-6. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5317657/pdf/edinbmedj74203-0079b.pdf
Type
1.
Kim, Ko. The treatment of the Foot Ulcer in Hansen’s Disease. Korean Leprosy Bulletin. 2001;34(2):35-57.
Type
1.
Seo, Lee, Yoon, Park. The decision for termination of leprosy treatment using reticulum stain of leprosy skin lesions. Korean Leprosy Bulletin. 2005;38(2):15-24.
Type
1.
Cerully J, Acosta J, Sloan J. Mental health stigma and its effects on treatment-related outcomes: A narrative review. Military medicine. 2018;.